RSS
4 Nov 2020

Alzinova AB announces the study design for the first clinical study with the oligomer-specific therapeutic vaccine ALZ-101 at a scientific congress

Author: admintech | Filed under: Press Release

STOCKHOLM, Nov. 4, 2020 /PRNewswire/ — Alzinova AB today announces the upcoming clinical study with the vaccine candidate ALZ-101 at the scientific congress Clinical Trials in Alzheimer’s Disease (CTAD). The planned study will be conducted in patients with early Alzheimer’s disease and…

This entry was posted on Wednesday, November 4th, 2020 at 7:21 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

«

»